IASO Biotechnology has signed a technology licensing agreement with the Instituto Butantan, a Brazilian public institution, for the local development of a CAR-T cell therapy for hematological cancer in Brazil. The technology uses the patient’s own immune cells to treat the disease. Under the agreement, the cells will be developed and manufactured at the Advanced Therapies Center of São Paulo (Nutera-SP), a facility coordinated by Butantan that has specific equipment for cell therapies. ...